Stock screener for investors and traders, financial visualizations.
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
Источник: http://finviz.com/quote.ashx?t=ARCT
Проанализируйте акцию Arcturus Therapeutics
по ключевым показателям
Анализ портфелей 508,074 инвесторов
Сделки инсайдеров и инсайдерский сигнал
Официальная отчетность по сделкам 4 хедж-фондов
Биржевые данные и финансовые показатели компании
Рейтинг инвестиционной привлекательности компании
Исторические данные и прогнозы по выплатам
Самые свежие новости и общая оценка новостного фона
Источник: http://beststocks.ru/stock/arct/comments
ARCT Overview
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases.
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$37.43 |
| 52 Week High | US$129.71 |
| 52 Week Low | US$24.87 |
| Beta | 2.67 |
| 1 Month Change | -15.41% |
| 3 Month Change | -22.05% |
| 1 Year Change | -22.22% |
| 3 Year Change | 452.07% |
| 5 Year Change | n/a |
| Change since IPO | 273.93% |
Recent News & Updates
Sep 10
Arcturus Therapeutics Presents Specific Asian COVID-19 Opportunity
The company has a specific opportunity to be a vaccine supplier within Asia and to the world.Re-instated trials are proceeding after disappointment earlier in the year.As a well-capitalised company, there should be no shareholder risk dilution for a couple of years.Company is targeting a range of conditions with its patented mRNA technology, not just COVID-19.The month of August saw a series of promising developments for the company.
Shareholder Returns
| ARCT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -16.3% | -5.5% | -0.7% |
| 1Y | -22.2% | 8.2% | 30.0% |
Return vs Industry: ARCT underperformed the US Biotechs industry which returned 8.2% over the past year.
Return vs Market: ARCT underperformed the US Market which returned 30% over the past year.
Price Volatility
| ARCT volatility | |
|---|---|
| ARCT Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 2.2% |
Stable Share Price: ARCT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: ARCT’s weekly volatility has decreased from 19% to 9% over the past year.
About the Company
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Its preclinical drug discovery and development programs include LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 209 patents and patent applications, issued in the United States and other countries.
Arcturus Therapeutics Holdings Fundamentals Summary
| ARCT fundamental statistics | |
|---|---|
| Market Cap | US$986.67m |
| Earnings (TTM) | -US$196.11m |
| Revenue (TTM) | US$8.80m |
Earnings & Revenue
| ARCT income statement (TTM) | |
|---|---|
| Revenue | US$8.80m |
| Cost of Revenue | US$57.85m |
| Gross Profit | -US$49.04m |
| Expenses | US$147.07m |
| Earnings | -US$196.11m |
Last Reported Earnings
Sep 30, 2021
| Earnings per share (EPS) | -7.44 |
| Gross Margin | -557.12% |
| Net Profit Margin | -2,227.82% |
| Debt/Equity Ratio | 23.5% |
How did ARCT perform over the long term?
See historical performance and comparison
Источник: http://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arct/arcturus-therapeutics-holdings
LUNAR®-mediated delivery of RNA into cells
LUNAR® particles associate with the cell membrane of a target cell of interest and quickly enter the cell via endocytosis.
Upon entering the cytosol, the LUNAR® formulations then become trapped in the endosomes.
With increased acidity as the endosome ages, a pH-mediated disruption enables release of the RNA payload following rapid biodegradation of the LUNAR®components.
Once release of the RNA into the cytosol occurs, the translational machinery can interact with the RNA and processing and/or trafficking can then take place to make functional protein.
LUNAR® lipid mediated delivery enables delivery of RNA medicines.
Источник: http://arcturusrx.com/
What happened
Shares of Arcturus Therapeutics Holdings (NASDAQ:ARCT) were plunging 53.7% as of 11:16 a.m. EST on Tuesday. The huge decline came after the biotech reported data from an early-stage clinical study of COVID-19 vaccine candidate ARCT-021.
Источник: http://fool.com/investing/2020/12/29/why-arcturus-therapeutics-stock-is-plunging-today/
Другие компании сектора Биотехнологии
В таблице представлены только акции, торгующиеся на Санкт-Петербургской бирже, за исключением российских.
Источник: http://finbull.ru/stock/ARCT/
External links[edit]
- Business Data for Arcturus Therapeutics: Yahoo Finance Reuters Bloomberg Nasdaq SEC Filings
Источник: http://en.wikipedia.org/wiki/Arcturus_Therapeutics
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.6%.
Top Shareholders
Источник: http://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arct/arcturus-therapeutics-holdings
Company Information
Arcturus Therapeutics Holdings Inc.’s employee growth, exchange listings and data sources
Key Information
- Name: Arcturus Therapeutics Holdings Inc.
- Ticker: ARCT
- Exchange: NasdaqGM
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$986.674m
- Shares outstanding: 26.36m
- Website: https://www.arcturusrx.com
Number of Employees
Location
- Arcturus Therapeutics Holdings Inc.
- 10628 Science Center Drive
- Suite 250
- San Diego
- California
- 92121
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/11/12 00:09 |
| End of Day Share Price | 2021/11/11 00:00 |
| Earnings | 2021/09/30 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Источник: http://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arct/arcturus-therapeutics-holdings